Low-dose colchicine (0.5mg daily) reduced major cardiovascular events by 31% in the LoDoCo2 trial by inhibiting neutrophil-driven vascular inflammation. It represents the most clinically validated anti-inflammatory strategy in chronic atherosclerosis.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.